Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
Offord
Robin
R
Guy's and St. Thomas' Hospital Trust, London, SE1 7EH, UK. robin.offord@gstt.sthames.nhs.uk
Lloyd
Adam C
AC
Anderson
Pippa
P
Bearne
Andy
A
D000208:Acute Disease; D000368:Aged; D003362:Cost-Benefit Analysis / Q000379:methods*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D017984:Enoxaparin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D017721:Hospital Costs; D006784:Hospitals, Teaching / Q000191:economics; D006801:Humans; D007267:Injections; D007297:Inpatients; D018803:Models, Economic; D018579:Patient Selection; D010607:Pharmacy Service, Hospital / Q000191:economics; D013923:Thromboembolism / Q000191:economics / Q000517:prevention & control*; D006113:United Kingdom; D020246:Venous Thrombosis / Q000191:economics / Q000517:prevention & control*
D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight